Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 6/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468832 | 0.90 | CYP11B2 (0.52) | EGLN2ACACBGPR119CYP11B2PARP1 | |
| SCHEMBL20468837 | 0.90 | CYP11B2 (0.49) | EGLN2ACACBGPR119CYP11B2PARP1 | |
| SCHEMBL21590381 | 0.89 | EGLN2 (0.44) | EGLN2ACACBGPR119CYP11B2PARP1 | |
| SCHEMBL20469135 | 0.86 | CYP11B2 (0.53) | ACACBCYP11B2PARP1SCD5RET | |
| SCHEMBL21711129 | 0.86 | CYP11B2 (0.53) | ACACBCYP11B2PARP1SCD5RET | |
| SCHEMBL12811247 | 0.85 | EGLN2 (0.48) | EGLN2ACACBGPR119CYP11B2KRAS | |
| SCHEMBL21667796 | 0.82 | MAPT (0.54) | EGLN2GPR119 | |
| SCHEMBL30328000 | 0.81 | CYP11B2 (0.46) | ACACBGPR119CYP11B2SCD5 | |
| SCHEMBL27031070 | 0.81 | GPR119 (0.60) | EGLN2GPR119CYP11B2 | |
| SCHEMBL13015255 | 0.81 | MAPT (0.47) | EGLN2ACACBGPR119CYP11B2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3600290-B1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240300954-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-09-12 | — | — | US | disclosed |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-25 | — | — | US | disclosed |
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-06 | — | — | US | disclosed |
| EP-3600290-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175188-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | EGLN2 3249/4885ACACB 2081/4885GPR119 61/4885 |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | EGLN2 2849/4885ACACB 1763/4885GPR119 25/4885 |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | EGLN2 2849/4885ACACB 1763/4885GPR119 25/4885 |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | EGLN2 3249/4885ACACB 2081/4885GPR119 61/4885 |
| US-20240300954-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | EGLN2 2849/4885ACACB 1763/4885GPR119 25/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | EGLN2 4236/4885ACACB 1664/4885GPR119 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.